ATE446090T1 - Thiadiazolidinone als gsk3-inhibitoren - Google Patents

Thiadiazolidinone als gsk3-inhibitoren

Info

Publication number
ATE446090T1
ATE446090T1 AT05075779T AT05075779T ATE446090T1 AT E446090 T1 ATE446090 T1 AT E446090T1 AT 05075779 T AT05075779 T AT 05075779T AT 05075779 T AT05075779 T AT 05075779T AT E446090 T1 ATE446090 T1 AT E446090T1
Authority
AT
Austria
Prior art keywords
thiadiazolidinones
gsk3 inhibitors
gsk3
inhibitors
Prior art date
Application number
AT05075779T
Other languages
English (en)
Inventor
Gil Martinez
Diaz Isabel Dorronsoro
Cascon Mercedes Alonso
Pliego Gema Panizodel
Huerta Ana Fuertes
Puerto Maria Jose Perez
Padilla Miguel Medina
Original Assignee
Noscira Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE446090(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noscira Sa filed Critical Noscira Sa
Application granted granted Critical
Publication of ATE446090T1 publication Critical patent/ATE446090T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
AT05075779T 2004-04-05 2005-04-04 Thiadiazolidinone als gsk3-inhibitoren ATE446090T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04075997A EP1586318A1 (de) 2004-04-05 2004-04-05 Thiadiazolidinone als GSK3-Inhibitoren

Publications (1)

Publication Number Publication Date
ATE446090T1 true ATE446090T1 (de) 2009-11-15

Family

ID=34928129

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05075779T ATE446090T1 (de) 2004-04-05 2005-04-04 Thiadiazolidinone als gsk3-inhibitoren

Country Status (30)

Country Link
US (2) US7531561B2 (de)
EP (2) EP1586318A1 (de)
JP (1) JP4995076B2 (de)
KR (1) KR101151647B1 (de)
CN (1) CN1946398B (de)
AR (2) AR048820A1 (de)
AT (1) ATE446090T1 (de)
AU (1) AU2005230392B2 (de)
BR (1) BRPI0508788A (de)
CA (1) CA2559740C (de)
CY (1) CY1109724T1 (de)
DE (1) DE602005017215D1 (de)
DK (1) DK1586319T3 (de)
EC (1) ECSP066858A (de)
ES (1) ES2335505T3 (de)
HK (1) HK1100426A1 (de)
HR (1) HRP20100032T1 (de)
IL (1) IL178125A (de)
MA (1) MA28515B1 (de)
MX (1) MXPA06011194A (de)
NO (1) NO332751B1 (de)
NZ (1) NZ549904A (de)
PL (1) PL1586319T3 (de)
PT (1) PT1586319E (de)
RS (1) RS51340B (de)
RU (1) RU2379300C2 (de)
SI (1) SI1586319T1 (de)
TW (1) TWI352084B (de)
WO (1) WO2005097117A1 (de)
ZA (1) ZA200608221B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110734A (pt) 2000-05-11 2003-02-04 Consejo Superior Investigacion Inibidores heterocìclicos de cinase de sintase de glicogênio gsk-3
EP1586318A1 (de) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinone als GSK3-Inhibitoren
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
ES2258406B1 (es) * 2005-02-10 2007-12-01 Neuropharma, S.A. Uso de compuestos heterociclicos como agentes neurogenicos.
EP1749523A1 (de) * 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 Inhibitoren
CA2658263A1 (en) * 2006-07-18 2008-01-24 University Of Rochester Thiadiazolidinone derivatives
WO2008012031A2 (en) * 2006-07-25 2008-01-31 Universität Bern Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
JP5406030B2 (ja) 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
KR100829468B1 (ko) * 2007-01-17 2008-05-16 한국화학연구원 신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2177510A1 (de) 2008-10-17 2010-04-21 Universität des Saarlandes Allosterische Proteinkinasemodulatoren
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2621914B1 (de) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als glycogensynthasekinase-3-inhibitoren
WO2012065065A1 (en) * 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
US20140079686A1 (en) 2010-12-06 2014-03-20 Shikha P. Barman Methods For Treating Baldness And Promoting Hair Growth
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8865750B2 (en) 2011-04-28 2014-10-21 The Regents Of The University Of Michigan Small molecule inhibitors of RGS proteins
EP2527323A1 (de) 2011-05-24 2012-11-28 Noscira, S.A. Harnstoffcarbonyldisulfidderivate und deren therapeutische Verwendungen
WO2012170657A1 (en) * 2011-06-07 2012-12-13 Georgetown University Targeting gsk-3beta for the treatment of parkinson's disease
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
ES2632428T3 (es) 2012-02-24 2017-09-13 Asd Therapeutics Partners Llc Nuevas tiadiazolidinadionas como inhibidores de GSK-3
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
CN103992313A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
WO2015075051A1 (en) 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
KR102567244B1 (ko) * 2014-06-12 2023-08-16 세다르스-신나이 메디칼 센터 암을 치료하는 조성물 및 방법
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
CA3017341A1 (en) * 2016-03-10 2017-09-14 Alma Mater Studiorum - Universita Di Bologna Treatment of cdkl5 disorders with gsk3.beta. inhibitor tideglusib
US11590110B2 (en) * 2017-06-06 2023-02-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113827592A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种噻二唑烷二酮基化合物在治疗致病性感染中的应用
EP4298088A1 (de) 2021-02-24 2024-01-03 Teva Pharmaceuticals International GmbH Feste formen von tideglusib und verfahren zu deren herstellung
US20220387399A1 (en) 2021-05-21 2022-12-08 Amo Pharma Ltd. Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (de) 2021-05-24 2022-11-30 Consejo Superior De Investigaciones Científicas Thiadiazolidinone zur verwendung in der behandlung von gliedergürtel-muskeldystrophie
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110734A (pt) * 2000-05-11 2003-02-04 Consejo Superior Investigacion Inibidores heterocìclicos de cinase de sintase de glicogênio gsk-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
EP1586318A1 (de) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinone als GSK3-Inhibitoren

Also Published As

Publication number Publication date
CY1109724T1 (el) 2014-08-13
BRPI0508788A (pt) 2007-09-04
US20090233971A1 (en) 2009-09-17
CA2559740C (en) 2014-06-10
ZA200608221B (en) 2008-08-27
CA2559740A1 (en) 2005-10-20
CN1946398B (zh) 2011-03-30
AU2005230392A1 (en) 2005-10-20
IL178125A (en) 2012-01-31
EP1586319B1 (de) 2009-10-21
HRP20100032T1 (hr) 2010-03-31
MA28515B1 (fr) 2007-04-03
US8158661B2 (en) 2012-04-17
NO20064456L (no) 2006-10-02
MXPA06011194A (es) 2007-03-21
JP4995076B2 (ja) 2012-08-08
TW200538119A (en) 2005-12-01
RU2006139030A (ru) 2008-05-20
EP1586318A1 (de) 2005-10-19
US20050222220A1 (en) 2005-10-06
DK1586319T3 (da) 2010-02-08
IL178125A0 (en) 2006-12-31
TWI352084B (en) 2011-11-11
PL1586319T3 (pl) 2010-06-30
PT1586319E (pt) 2010-01-21
DE602005017215D1 (de) 2009-12-03
ECSP066858A (es) 2007-01-26
RU2379300C2 (ru) 2010-01-20
JP2007531782A (ja) 2007-11-08
AR048820A1 (es) 2006-05-31
US7531561B2 (en) 2009-05-12
AU2005230392B2 (en) 2011-03-24
NO332751B1 (no) 2013-01-07
AR104417A2 (es) 2017-07-19
CN1946398A (zh) 2007-04-11
SI1586319T1 (sl) 2010-02-26
KR101151647B1 (ko) 2012-06-08
RS51340B (en) 2011-02-28
ES2335505T3 (es) 2010-03-29
KR20060131976A (ko) 2006-12-20
HK1100426A1 (en) 2007-09-21
EP1586319A1 (de) 2005-10-19
NZ549904A (en) 2010-08-27
WO2005097117A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
ATE446090T1 (de) Thiadiazolidinone als gsk3-inhibitoren
CY2019034I1 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
DE602005002517D1 (de) Drehtisch
DE602005004287D1 (de) Pyrrazolopyrimidinderivate
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
ATE459633T1 (de) Makrolide
AT500198B1 (de) Ladewagen
ATE389633T1 (de) Omega-phenyloctanamide
FI20050681A (fi) Paikoitusmenetelmä
AT500249A3 (de) Scheibenegge
ATE454934T1 (de) Drehteller
DE502004001961D1 (de) Barikadenbrecher
DE112005002245A5 (de) Polymerdichtung
SE0403198D0 (sv) Analyzer
ATA482004A (de) Tuba-dämpfer
AT7802U3 (de) Parfum-zerstäuber
ATA9982004A (de) Tiefbohrbrunnen
DE602005017159D1 (de) Oxysteroid-dehydrogenase-inhibitoren
ES1059458Y (es) Marcapaginas ex libris

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1586319

Country of ref document: EP